FLD-103 Treatment for Basal Cell Carcinoma
Basal Cell Carcinoma (BCC) at a Glance
BCC is the most common form of skin cancer, and the most common type of all cancers.
Affects 3.6 million people each
year in North America
Primarily caused by
cumulative sun exposure
Most commonly develops on
sun exposed areas such as the
face, neck, and scalp
There remains a need for treatments
that preserve skin, minimize
discomfort, and allow patients
to return to their daily lives promptly
BCC Subtypes and Treatments
BCCs start in basal layer of the skin and can appear in different forms depending on how they grow within the skin layers.
Superficial BCC (≈15% of cases)
Usually treated with topical medications, such as creams, applied directly to the skin.
Advanced or Metastatic BCC (≈1-10% of cases)
Treated with systemic therapies such as Hedgehog pathway inhibitors, or surgery.
Nodular BCC (≈60-80% of cases)
Most often treated with surgical excision. Mohs surgery, often referred as the gold standard, offers the highest precision and lower risk of recurrence.
Understanding Nodular BCC Care
While Mohs surgery is effective, it is a surgical procedure that can take many hours, requires preparation, may cause discomfort, and involves a recovery period. Lasting changes to the treated skin, such as scarring, discoloration, and disfigurement, can occur, and healing may take several weeks to months. For patients with multiple or recurring nodular BCCs, repeated procedures are required over time, which can become physically and emotionally demanding. Although surgery remains the primary treatment option for nodular BCC, it is not suitable for all basal cell carcinoma lesions or patients.
This underscores the need for treatments that preserve skin integrity and lead to better outcomes for patients.

FLD-103: An Investigational Non-Surgical Treatment for nBCC by Feldan Therapeutics
Injected directly into nBCC tumors, FLD-103 is developed to preserve skin health and integrity while minimizing discomfort and disruption to patients' daily lives.
Skin Integrity
Administered through injections to preserve the health and appearance of skin
Minimal Recovery
Non-surgical procedure allows patients to get back to daily activities quickly
Reduced Time-to-Treatment
Available through more dermatology practices
Our cells use different signaling systems to guide how they grow and develop. In healthy adult skin, one of these systems—called the Hedgehog pathway—is usually switched off. In basal cell carcinoma, a change in the DNA causes this pathway to become abnormally active, sending signals that drive cancer cell growth.
FLD-103 has been developed to block a key component of this pathway, helping to slow or stop the abnormal growth of cancer cells.

FLD-103 Clinical Trial Status
FLD-103 is an investigational treatment currently being evaluated in clinical trials. It is not yet approved for general use.
*This page provides patients and families general information about these conditions, as well as insights into our innovative therapies and the ways they are developed — presented in an informative and supportive manner, while never replacing personalized medical advice.



